This is the authors' abstract. We don't add key points for this paper.
Griscelli syndrome type 2 (GS2) is a life-threatening disease caused by mutations in the RAB27A gene. It is characterized by partial albinism in association with systemic immunological abnormalities leading to hemophagocytic lymphohistiocytosis (HLH). Variable neurological impairment is experienced by patients suffering from HLH and neurological symptoms can be the main manifestations of the disease. We describe a 3 years-old child suffering from a relapsing-remitting multifocal encephalomyelopathy with mild systemic signs. He was not “albino” even if he had very light hair and eyes respect to his parents. He was initially treated with steroids; symptoms wax and wane for months. Than there was a sudden worsening in the general condition of the child. Despite the paucity of systemic signs (a mild and not persistent cytopenia), a HLH was considered and an extensive diagnostic workup, including a brain biopsy, allowed the diagnosis of GS2. Unfortunately, the patient died due to the severity of his clinical condition. RAB27A mutations results in wide phenotypic heterogeneity. Usually systemic symptoms are early present in the disease. Since steroids are normally administered from the beginning in case of inflammatory neurological disorders, it should be noted that they can mask systemic features. GS2 should be considered in the diagnosis of inflammatory progressive neurological disease, especially in young children.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Tozzo et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: